Stock Events

Stock Events

Innovation1 Biotech 

$0.000200
4
+$0.00+0%Monday 21:00
+$0.00+0%Thursday 19:55Pre-market

Statistics

Day High
0.0002
Day Low
0.0002
52W High
0.0002
52W Low
0.0002
Volume
153
Avg. Volume
0
Mkt Cap
4,494
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Dec 15Expected
Q3 2020
Q1 2021
Q2 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-2.46
-0.23
1.99
4.22
Expected EPS
N/A
Actual EPS
-2.46

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
0Revenue
-14.08MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap75.86B
Moderna is a leader in mRNA technology, directly competing with IVBT's focus on innovative biotech solutions.
BioNTech
BNTX
Mkt Cap24.34B
BioNTech competes in the biotechnology space, especially in the development of vaccines, similar to IVBT's efforts.
Novavax
NVAX
Mkt Cap1.73B
Novavax is involved in the development of vaccines for infectious diseases, competing with IVBT's biotech research.
CRISPR Therapeutics
CRSP
Mkt Cap5.36B
CRISPR Therapeutics is a competitor due to its focus on gene editing, a cutting-edge area of biotech where IVBT may also be involved.
Intellia Therapeutics
NTLA
Mkt Cap1.72B
Intellia Therapeutics competes with IVBT in the gene editing space, utilizing CRISPR/Cas9 technology.
Editas Medicine
EDIT
Mkt Cap402.38M
Editas Medicine is a direct competitor in the gene editing market, potentially overlapping with IVBT's biotech innovations.
Alnylam Pharmaceuticals
ALNY
Mkt Cap29.4B
Alnylam Pharmaceuticals competes in the RNAi therapeutic space, which could intersect with IVBT's biotech research areas.
Sarepta Therapeutics
SRPT
Mkt Cap1.85B
Sarepta Therapeutics, focusing on genetic medicine for rare diseases, competes with IVBT's innovative biotech solutions.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.93B
Vertex Pharmaceuticals is involved in creating transformative medicines, potentially competing with IVBT's biotech research.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals is known for its innovative biotech treatments, competing with IVBT in the broader biotech industry.

About

Innovation1 Biotech Inc. functions as a drug discovery enterprise, primarily engaged in creating modified botanical Schedule 1 molecules for use within the United States. The firm's pipeline encompasses five entirely synthetic, proprietary prodrugs that are currently in preclinical development, each designed to tackle a unique set of medical conditions. Specifically, these include a psychedelic compound derived from mushrooms, aimed at treating post-traumatic stress disorder and depression; an innovative cannabinoid and tree bark-sourced psychedelic intended to combat addiction; and three additional cannabinoid prodrugs targeting refractory pediatric epilepsy, hypertrophic scarring, and inflammation of the eye. Established in 2014 and headquartered in New York, New York, the company was previously named Gridiron BioNutrients, Inc. before adopting its current moniker, Innovation1 Biotech Inc., in March 2022.
Show More
CEO
Francis Knuettel
Employees
1
Country
United States
ISIN
US39809D2018

Listings

OTC Link
US
IVBT

0 Comments

Share your thoughts

FAQs

What is Innovation1 Biotech stock price today?▼
The current price of IVBT is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Innovation1 Biotech stock price performance more closely on the chart.
What is Innovation1 Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Innovation1 Biotech stocks are traded under the ticker IVBT.
Is Innovation1 Biotech stock price growing?▼
IVBT stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Innovation1 Biotech has showed a +0% increase.
What is Innovation1 Biotech market cap?▼
Today Innovation1 Biotech has the market capitalization of 4,494
What were Innovation1 Biotech earnings last quarter?▼
IVBT earnings for the last quarter are -2.46 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Innovation1 Biotech revenue for the last year?▼
Innovation1 Biotech revenue for the last year amounts to 0 USD.
What is Innovation1 Biotech net income for the last year?▼
IVBT net income for the last year is -14.08M USD.
How many employees does Innovation1 Biotech have?▼
As of November 2, 2026, the company has 1 employees.
In which sector is Innovation1 Biotech located?▼
Innovation1 Biotech operates in the Finance & Payments sector.
When did Innovation1 Biotech complete a stock split?▼
The last stock split for Innovation1 Biotech was on January 12, 2021 with a ratio of 1:308.
Where is Innovation1 Biotech headquartered?▼
Innovation1 Biotech is headquartered in New York, United States.